Company intelligence / Profile preview

enGen

Redwood City, California, United States

Ownership: Private
Development stage: Other

Overview

EnGen Bio has achieved positive results in preclinical trials for a universal Type A influenza vaccine, showing significant protection in animal models. The vaccine targets a novel epitope on the M1 matrix protein of the influenza virus.

Therapeutic areas: Infectious Diseases
Modalities: VaccineMonoclonal antibody
Industry: Biotech

Beyond the preview

Go deeper on enGen.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on enGen.

Explore the full profile